1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Psychedelic Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Psilocybin
1.2.3 LSD
1.2.4 MDMA
1.2.5 DMT
1.2.6 Ketamine
1.2.7 Others
1.3 Market by Application
1.3.1 Global Psychedelic Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Depressive Disorders
1.3.3 Post-Traumatic Stress Disorders
1.3.4 Substance Abuse Disorders
1.3.5 Obsessive Compulsive Disorders
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Psychedelic Drugs Market Perspective (2017-2028)
2.2 Psychedelic Drugs Growth Trends by Region
2.2.1 Psychedelic Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Psychedelic Drugs Historic Market Size by Region (2017-2022)
2.2.3 Psychedelic Drugs Forecasted Market Size by Region (2023-2028)
2.3 Psychedelic Drugs Market Dynamics
2.3.1 Psychedelic Drugs Industry Trends
2.3.2 Psychedelic Drugs Market Drivers
2.3.3 Psychedelic Drugs Market Challenges
2.3.4 Psychedelic Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Psychedelic Drugs Players by Revenue
3.1.1 Global Top Psychedelic Drugs Players by Revenue (2017-2022)
3.1.2 Global Psychedelic Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Psychedelic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Psychedelic Drugs Revenue
3.4 Global Psychedelic Drugs Market Concentration Ratio
3.4.1 Global Psychedelic Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Psychedelic Drugs Revenue in 2021
3.5 Psychedelic Drugs Key Players Head office and Area Served
3.6 Key Players Psychedelic Drugs Product Solution and Service
3.7 Date of Enter into Psychedelic Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Psychedelic Drugs Breakdown Data by Type
4.1 Global Psychedelic Drugs Historic Market Size by Type (2017-2022)
4.2 Global Psychedelic Drugs Forecasted Market Size by Type (2023-2028)
5 Psychedelic Drugs Breakdown Data by Application
5.1 Global Psychedelic Drugs Historic Market Size by Application (2017-2022)
5.2 Global Psychedelic Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Psychedelic Drugs Market Size (2017-2028)
6.2 North America Psychedelic Drugs Market Size by Type
6.2.1 North America Psychedelic Drugs Market Size by Type (2017-2022)
6.2.2 North America Psychedelic Drugs Market Size by Type (2023-2028)
6.2.3 North America Psychedelic Drugs Market Share by Type (2017-2028)
6.3 North America Psychedelic Drugs Market Size by Application
6.3.1 North America Psychedelic Drugs Market Size by Application (2017-2022)
6.3.2 North America Psychedelic Drugs Market Size by Application (2023-2028)
6.3.3 North America Psychedelic Drugs Market Share by Application (2017-2028)
6.4 North America Psychedelic Drugs Market Size by Country
6.4.1 North America Psychedelic Drugs Market Size by Country (2017-2022)
6.4.2 North America Psychedelic Drugs Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Psychedelic Drugs Market Size (2017-2028)
7.2 Europe Psychedelic Drugs Market Size by Type
7.2.1 Europe Psychedelic Drugs Market Size by Type (2017-2022)
7.2.2 Europe Psychedelic Drugs Market Size by Type (2023-2028)
7.2.3 Europe Psychedelic Drugs Market Share by Type (2017-2028)
7.3 Europe Psychedelic Drugs Market Size by Application
7.3.1 Europe Psychedelic Drugs Market Size by Application (2017-2022)
7.3.2 Europe Psychedelic Drugs Market Size by Application (2023-2028)
7.3.3 Europe Psychedelic Drugs Market Share by Application (2017-2028)
7.4 Europe Psychedelic Drugs Market Size by Country
7.4.1 Europe Psychedelic Drugs Market Size by Country (2017-2022)
7.4.2 Europe Psychedelic Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Psychedelic Drugs Market Size (2017-2028)
8.2 Asia-Pacific Psychedelic Drugs Market Size by Type
8.2.1 Asia-Pacific Psychedelic Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Psychedelic Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Psychedelic Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific Psychedelic Drugs Market Size by Application
8.3.1 Asia-Pacific Psychedelic Drugs Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Psychedelic Drugs Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Psychedelic Drugs Market Share by Application (2017-2028)
8.4 Asia-Pacific Psychedelic Drugs Market Size by Region
8.4.1 Asia-Pacific Psychedelic Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Psychedelic Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Psychedelic Drugs Market Size (2017-2028)
9.2 Latin America Psychedelic Drugs Market Size by Type
9.2.1 Latin America Psychedelic Drugs Market Size by Type (2017-2022)
9.2.2 Latin America Psychedelic Drugs Market Size by Type (2023-2028)
9.2.3 Latin America Psychedelic Drugs Market Share by Type (2017-2028)
9.3 Latin America Psychedelic Drugs Market Size by Application
9.3.1 Latin America Psychedelic Drugs Market Size by Application (2017-2022)
9.3.2 Latin America Psychedelic Drugs Market Size by Application (2023-2028)
9.3.3 Latin America Psychedelic Drugs Market Share by Application (2017-2028)
9.4 Latin America Psychedelic Drugs Market Size by Country
9.4.1 Latin America Psychedelic Drugs Market Size by Country (2017-2022)
9.4.2 Latin America Psychedelic Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Psychedelic Drugs Market Size (2017-2028)
10.2 Middle East & Africa Psychedelic Drugs Market Size by Type
10.2.1 Middle East & Africa Psychedelic Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Psychedelic Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Psychedelic Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa Psychedelic Drugs Market Size by Application
10.3.1 Middle East & Africa Psychedelic Drugs Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Psychedelic Drugs Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Psychedelic Drugs Market Share by Application (2017-2028)
10.4 Middle East & Africa Psychedelic Drugs Market Size by Country
10.4.1 Middle East & Africa Psychedelic Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Psychedelic Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 COMPASS Pathways PLC
11.1.1 COMPASS Pathways PLC Company Details
11.1.2 COMPASS Pathways PLC Business Overview
11.1.3 COMPASS Pathways PLC Psychedelic Drugs Introduction
11.1.4 COMPASS Pathways PLC Revenue in Psychedelic Drugs Business (2017-2022)
11.1.5 COMPASS Pathways PLC Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Psychedelic Drugs Introduction
11.2.4 Pfizer Revenue in Psychedelic Drugs Business (2017-2022)
11.2.5 Pfizer Recent Developments
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Psychedelic Drugs Introduction
11.3.4 Eli Lilly Revenue in Psychedelic Drugs Business (2017-2022)
11.3.5 Eli Lilly Recent Developments
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Psychedelic Drugs Introduction
11.4.4 GlaxoSmithKline Revenue in Psychedelic Drugs Business (2017-2022)
11.4.5 GlaxoSmithKline Recent Developments
11.5 Cybin Inc
11.5.1 Cybin Inc Company Details
11.5.2 Cybin Inc Business Overview
11.5.3 Cybin Inc Psychedelic Drugs Introduction
11.5.4 Cybin Inc Revenue in Psychedelic Drugs Business (2017-2022)
11.5.5 Cybin Inc Recent Developments
11.6 Field Trip Health
11.6.1 Field Trip Health Company Details
11.6.2 Field Trip Health Business Overview
11.6.3 Field Trip Health Psychedelic Drugs Introduction
11.6.4 Field Trip Health Revenue in Psychedelic Drugs Business (2017-2022)
11.6.5 Field Trip Health Recent Developments
11.7 ATAI Life Sciences
11.7.1 ATAI Life Sciences Company Details
11.7.2 ATAI Life Sciences Business Overview
11.7.3 ATAI Life Sciences Psychedelic Drugs Introduction
11.7.4 ATAI Life Sciences Revenue in Psychedelic Drugs Business (2017-2022)
11.7.5 ATAI Life Sciences Recent Developments
11.8 NUMINUS WELLNESS
11.8.1 NUMINUS WELLNESS Company Details
11.8.2 NUMINUS WELLNESS Business Overview
11.8.3 NUMINUS WELLNESS Psychedelic Drugs Introduction
11.8.4 NUMINUS WELLNESS Revenue in Psychedelic Drugs Business (2017-2022)
11.8.5 NUMINUS WELLNESS Recent Developments
11.9 MindMed
11.9.1 MindMed Company Details
11.9.2 MindMed Business Overview
11.9.3 MindMed Psychedelic Drugs Introduction
11.9.4 MindMed Revenue in Psychedelic Drugs Business (2017-2022)
11.9.5 MindMed Recent Developments
11.10 HAVN Life Sciences
11.10.1 HAVN Life Sciences Company Details
11.10.2 HAVN Life Sciences Business Overview
11.10.3 HAVN Life Sciences Psychedelic Drugs Introduction
11.10.4 HAVN Life Sciences Revenue in Psychedelic Drugs Business (2017-2022)
11.10.5 HAVN Life Sciences Recent Developments
11.11 Seelos Therapeutics
11.11.1 Seelos Therapeutics Company Details
11.11.2 Seelos Therapeutics Business Overview
11.11.3 Seelos Therapeutics Psychedelic Drugs Introduction
11.11.4 Seelos Therapeutics Revenue in Psychedelic Drugs Business (2017-2022)
11.11.5 Seelos Therapeutics Recent Developments
11.12 Jannsen
11.12.1 Jannsen Company Details
11.12.2 Jannsen Business Overview
11.12.3 Jannsen Psychedelic Drugs Introduction
11.12.4 Jannsen Revenue in Psychedelic Drugs Business (2017-2022)
11.12.5 Jannsen Recent Developments
11.13 Acadia Pharmaceuticals
11.13.1 Acadia Pharmaceuticals Company Details
11.13.2 Acadia Pharmaceuticals Business Overview
11.13.3 Acadia Pharmaceuticals Psychedelic Drugs Introduction
11.13.4 Acadia Pharmaceuticals Revenue in Psychedelic Drugs Business (2017-2022)
11.13.5 Acadia Pharmaceuticals Recent Developments
11.14 Intellipharmaceutics
11.14.1 Intellipharmaceutics Company Details
11.14.2 Intellipharmaceutics Business Overview
11.14.3 Intellipharmaceutics Psychedelic Drugs Introduction
11.14.4 Intellipharmaceutics Revenue in Psychedelic Drugs Business (2017-2022)
11.14.5 Intellipharmaceutics Recent Developments
11.15 Revive Therapeutics
11.15.1 Revive Therapeutics Company Details
11.15.2 Revive Therapeutics Business Overview
11.15.3 Revive Therapeutics Psychedelic Drugs Introduction
11.15.4 Revive Therapeutics Revenue in Psychedelic Drugs Business (2017-2022)
11.15.5 Revive Therapeutics Recent Developments
11.16 Mydecine Innovations Group
11.16.1 Mydecine Innovations Group Company Details
11.16.2 Mydecine Innovations Group Business Overview
11.16.3 Mydecine Innovations Group Psychedelic Drugs Introduction
11.16.4 Mydecine Innovations Group Revenue in Psychedelic Drugs Business (2017-2022)
11.16.5 Mydecine Innovations Group Recent Developments
11.17 Red Light Holland
11.17.1 Red Light Holland Company Details
11.17.2 Red Light Holland Business Overview
11.17.3 Red Light Holland Psychedelic Drugs Introduction
11.17.4 Red Light Holland Revenue in Psychedelic Drugs Business (2017-2022)
11.17.5 Red Light Holland Recent Developments
11.18 Braxia Scientific
11.18.1 Braxia Scientific Company Details
11.18.2 Braxia Scientific Business Overview
11.18.3 Braxia Scientific Psychedelic Drugs Introduction
11.18.4 Braxia Scientific Revenue in Psychedelic Drugs Business (2017-2022)
11.18.5 Braxia Scientific Recent Developments
11.19 Mind Cure Health
11.19.1 Mind Cure Health Company Details
11.19.2 Mind Cure Health Business Overview
11.19.3 Mind Cure Health Psychedelic Drugs Introduction
11.19.4 Mind Cure Health Revenue in Psychedelic Drugs Business (2017-2022)
11.19.5 Mind Cure Health Recent Developments
11.20 Entheon Biomedical
11.20.1 Entheon Biomedical Company Details
11.20.2 Entheon Biomedical Business Overview
11.20.3 Entheon Biomedical Psychedelic Drugs Introduction
11.20.4 Entheon Biomedical Revenue in Psychedelic Drugs Business (2017-2022)
11.20.5 Entheon Biomedical Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
